Table 2.
Clinical characteristics and laboratory findings of the patients at week 4 and 12.
| GP group | Placebo group | |||
|---|---|---|---|---|
| Week 4 | Week 12 | Week 4 | Week 12 | |
| n | 12 | 12 | 13 | 13 |
| Age (years) | 55.6 ± 9.9 | 55.6 ± 9.9 | 54.5 ± 8.4 | 54.5 ± 8.4 |
| Sex (Male : Female) | 7 : 5 | 7 : 5 | 8 : 5 | 8 : 5 |
| Body weight (kg) | 54.9 ± 6.9 | 55.1 ± 6.5 | 55.3 ± 11.4 | 54.8 ± 10.6 |
| BMI (kg/m2) | 21.8 ± 2.7 | 21.9 ± 2.7 | 22.5 ± 4.2 | 22.3 ± 4.0 |
| Waist (cm) | 85.8 ± 5.9 | 85.3 ± 5.6 | 87.3 ± 11.5 | 86.8 ± 10.7 |
| Hip (cm) | 95.3 ± 4.3 | 95.1 ± 4.2 | 97.3 ± 8.5 | 96.4 ± 8.4 |
| Systolic blood pressure (mmHg) | 123.5 ± 9.1 | 118.3 ± 9.4 | 119.2 ± 6.4 | 120.8 ± 9.5 |
| Diastolic bood pressure (mmHg) | 79.6 ± 5.3 | 75.4 ± 7.2 | 76.2 ± 5.1 | 77.7 ± 6.0 |
| Fasting plasma glucose (FPG) (mmol/L) | 9.6 ± 1.6 | 6.7 ± 0.4* | 9.0 ± 1.0 | 8.1 ± 1.0 |
| Fasting plasma insulin (pmol/L) | 120.0 ± 42.0 | 124.6 ± 49.0 | 131.4 ± 67.2 | 139.0 ± 89.9 |
| HOMA-IR | 8.5 ± 3.0 | 6.2 ± 2.4 | 9.0 ± 5.2 | 8.7 ± 6.4 |
| HOMA-β | 69.2 ± 28.4 | 131.5 ± 55.4 | 78.4 ± 38.4 | 97.3 ± 54.3 |
| HbA1C (%) | 9.0 ± 0.7 | 7.0 ± 0.7* | 8.8 ± 0.6 | 8.1 ± 0.6 |
| C-peptide (ng/mL) | 1.7 ± 0.7 | 1.8 ± 0.8 | 1.5 ± 0.8 | 1.8 ± 1.2 |
| 30-minute C-peptide (ng/mL) | 2.2 ± 1.3 | 2.7 ± 1.3 | 2.9 ± 1.3 | 3.2 ± 2.0 |
| Cholesterol (mmol/L) | 4.8 ± 1.1 | 4.9 ± 1.0 | 4.3 ± 0.8 | 4.3 ± 0.9 |
| Triglyceride (mmol/L) | 2.4 ± 1.5 | 2.3 ± 1.1 | 2.0 ± 1.2 | 2.0 ± 1.4 |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.4 | 1.2 ± 0.2 | 1.1 ± 0.2 | 1.1 ± 0.3 |
| LDL-cholesterol (mmol/L) | 2.8 ± 0.9 | 2.9 ± 0.6 | 2.3 ± 0.6 | 2.3 ± 0.6 |
Results are means ± SD, *P < 0.001.